Human Paraoxonase 1 (PON1) CLIA Kit | PON1 clia kit

Human Paraoxonase 1 (PON1) CLIA Kit

Cat. Num. AAA2708736

• Gene Names: PON1; ESA; PON; MVCD5
• Reactivity: Human
• Applications: Chemiluminescence Immunoassay (CLIA)
• Synonyms: Paraoxonase 1 (PON1); Human Paraoxonase 1 (PON1) CLIA Kit; Paraoxonase 1; ESA; PON; Esterase A; Serum paraoxonase/arylesterase 1; Aromatic esterase 1; A-esterase 1; Serum aryldialkylphosphatase 1; PON1 clia kit

• Reactivity: Human
• Specificity: This assay has high sensitivity and excellent specificity for detection of Paraoxonase 1 (PON1).; No significant cross-reactivity or interference between Paraoxonase 1 (PON1) and analogues was observed.
• Sequence Length: 3

• Applicable Applications for PON1 clia kit: Chemiluminescence Immunoassay (CLIA)
• Assay Type: Double-antibody Sandwich
• Samples: Serum, plasma and other biological fluids
• Detection Range: 0.27-200ng/mL
• Sensitivity: The minimum detectable dose of this kit is typically less than 0.11ng/mL
• Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Paraoxonase 1 (PON1) were tested 20 times on one plate, respectively.; Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Paraoxonase 1 (PON1) were tested on 3 different plates, 8 replicates in each plate.; CV(%) = SD/meanX100; Intra-Assay: CV<10%; Inter-Assay: CV<12%
• Test Principle: The microplate provided in this kit has been pre-coated with an antibody specific to Paraoxonase 1 (PON1). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Paraoxonase 1 (PON1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Paraoxonase 1 (PON1) level in the sample or standard.
• Preparation and Storage: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.; To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

NCBI and Uniprot Product Information

• NCBI GI #: 4105841
• NCBI GeneID: 5444
• UniProt Accession #: P27169
• NCBI Official Full Name: paraoxonase, partial
• NCBI Official Synonym Full Names: paraoxonase 1
• NCBI Official Symbol: PON1
• NCBI Official Synonym Symbols: ESA; PON; MVCD5
• NCBI Protein Information: serum paraoxonase/arylesterase 1
• UniProt Protein Name: Serum paraoxonase/arylesterase 1
• Protein Family: Serum paraoxonase/arylesterase
• UniProt Gene Name: PON1
• UniProt Synonym Gene Names: PON; PON 1
• UniProt Entry Name: PON1_HUMAN

NCBI Description

This gene encodes a member of the paraoxonase family of enzymes and exhibits lactonase and ester hydrolase activity. Following synthesis in the kidney and liver, the enzyme is secreted into the circulation, where it binds to high density lipoprotein (HDL) particles and hydrolyzes thiolactones and xenobiotics, including paraoxon, a metabolite of the insecticide parathion. Polymorphisms in this gene may be associated with coronary artery disease and diabetic retinopathy. The gene is found in a cluster of three related paraoxonase genes on chromosome 7. [provided by RefSeq, Aug 2017]

Uniprot Description

PON1: Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation. Genetic variation in PON1 is associated with susceptibility to microvascular complications of diabetes type 5 (MVCD5). These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new- onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Homozygosity for the Leu-54 allele is strongly associated with the development of retinal disease in diabetic patients. Belongs to the paraoxonase family.

Protein type: EC 3.1.8.1; EC 3.1.1.2; Lipid-binding; Secreted, signal peptide; Motility/polarity/chemotaxis; EC 3.1.1.81; Hydrolase; Phosphatase (non-protein); Secreted

Chromosomal Location of Human Ortholog: 7q21.3

Cellular Component: extracellular space; intracellular membrane-bound organelle; extracellular region

Molecular Function: protein homodimerization activity; arylesterase activity; phospholipid binding; calcium ion binding; aryldialkylphosphatase activity

Biological Process: response to external stimulus; response to nutrient levels; dephosphorylation; response to toxin; organophosphate catabolic process; positive regulation of transporter activity; carboxylic acid catabolic process; positive regulation of binding; aromatic compound catabolic process; phosphatidylcholine metabolic process

Disease: Microvascular Complications Of Diabetes, Susceptibility To, 5